CD8A and neoplasm: Avasimibe can augment the tumor-killing function of CD8+ T cells via the enhancement of T cell receptor (TCR) signaling and immunological synapse formation of CD8+ T cells by enhancing the cholesterol level of the plasma membrane (78).